Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Net Income towards Common Stockholders: 2017-2025

Historic Net Income towards Common Stockholders for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Sep 2025 value amounting to -$130.1 million.

  • Crinetics Pharmaceuticals' Net Income towards Common Stockholders fell 69.33% to -$130.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$422.7 million, marking a year-over-year decrease of 54.83%. This contributed to the annual value of -$297.4 million for FY2024, which is 42.19% down from last year.
  • As of Q3 2025, Crinetics Pharmaceuticals' Net Income towards Common Stockholders stood at -$130.1 million, which was down 12.48% from -$115.7 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of -$22.9 million in Q1 2021 and a low of -$130.1 million during Q3 2025.
  • In the last 3 years, Crinetics Pharmaceuticals' Net Income towards Common Stockholders had a median value of -$74.0 million in 2024 and averaged -$77.2 million.
  • Data for Crinetics Pharmaceuticals' Net Income towards Common Stockholders shows a maximum YoY slumped of 75.14% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Crinetics Pharmaceuticals' Net Income towards Common Stockholders stood at -$26.1 million in 2021, then slumped by 75.14% to -$45.7 million in 2022, then dropped by 22.53% to -$55.9 million in 2023, then plummeted by 43.69% to -$80.4 million in 2024, then plummeted by 69.33% to -$130.1 million in 2025.
  • Its Net Income towards Common Stockholders was -$130.1 million in Q3 2025, compared to -$115.7 million in Q2 2025 and -$96.6 million in Q1 2025.